Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Depletion of Tregs for adoptive T-cell therapy using CD44 and CD137 as selection markers.

Till BG, Press OW.

Immunotherapy. 2012 May;4(5):483-5. doi: 10.2217/imt.12.33.

2.

Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells.

Goldstein MJ, Kohrt HE, Houot R, Varghese B, Lin JT, Swanson E, Levy R.

Cancer Res. 2012 Mar 1;72(5):1239-47. doi: 10.1158/0008-5472.CAN-11-3375.

3.

Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses.

Hoelzinger DB, Smith SE, Mirza N, Dominguez AL, Manrique SZ, Lustgarten J.

J Immunol. 2010 Jun 15;184(12):6833-42. doi: 10.4049/jimmunol.0904084.

4.

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.

Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, Levy R.

Blood. 2009 Oct 15;114(16):3431-8. doi: 10.1182/blood-2009-05-223958.

5.

High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44(high) cells after their selective depletion.

Hong SH, Yoon IH, Kim YH, Yang SH, Park MJ, Nam HY, Kim B, Kim Y, Park CS, Park CG.

Immunobiology. 2010 Mar;215(3):182-93. doi: 10.1016/j.imbio.2009.01.010.

PMID:
19464751
6.

Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.

Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M, Lowenstein PR, Castro MG.

PLoS One. 2008 Apr 23;3(4):e1983. doi: 10.1371/journal.pone.0001983.

7.

Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.

Wehler TC, Nonn M, Brandt B, Britten CM, Gröne M, Todorova M, Link I, Khan SA, Meyer RG, Huber C, Hartwig UF, Herr W.

Blood. 2007 Jan 1;109(1):365-73.

8.

Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?

Weigelin B, Bolaños E, Rodriguez-Ruiz ME, Martinez-Forero I, Friedl P, Melero I.

Cancer Immunol Immunother. 2016 May;65(5):493-7. doi: 10.1007/s00262-016-1818-5.

PMID:
26970765
9.

Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice.

Darrasse-Jèze G, Bergot AS, Durgeau A, Billiard F, Salomon BL, Cohen JL, Bellier B, Podsypanina K, Klatzmann D.

J Clin Invest. 2009 Sep;119(9):2648-62. doi: 10.1172/JCI36628.

10.

Host CD25+CD4+Foxp3+ regulatory T cells primed by anti-CD137 mAbs inhibit graft-versus-host disease.

Kim J, Kim W, Kim HJ, Park S, Kim HA, Jung D, Choi HJ, Park SJ, Mittler RS, Cho HR, Kwon B.

Biol Blood Marrow Transplant. 2012 Jan;18(1):44-54. doi: 10.1016/j.bbmt.2011.09.004.

11.

Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia.

Baba J, Watanabe S, Saida Y, Tanaka T, Miyabayashi T, Koshio J, Ichikawa K, Nozaki K, Koya T, Deguchi K, Tan C, Miura S, Tanaka H, Tanaka J, Kagamu H, Yoshizawa H, Nakata K, Narita I.

Blood. 2012 Sep 20;120(12):2417-27.

12.

[Infusion of ex vivo expanded homologous CD4⁺;CD25⁺; regulatory T cells promotes the susceptibility to tumor in mice].

Guo T, Luo S, Xu J, Dai J, Liu Z, Gao X.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014 May;30(5):466-70. Chinese.

PMID:
24796739
13.

CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity.

Akhmetzyanova I, Zelinskyy G, Littwitz-Salomon E, Malyshkina A, Dietze KK, Streeck H, Brandau S, Dittmer U.

J Immunol. 2016 Jan 1;196(1):484-92. doi: 10.4049/jimmunol.1403039.

14.

Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity.

Yan X, Zhang X, Wang Y, Li X, Wang S, Zhao B, Li Y, Ju Y, Chen L, Liu W, Meng S.

Cancer Immunol Immunother. 2011 Dec;60(12):1763-74. doi: 10.1007/s00262-011-1076-5.

PMID:
21789592
15.

Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.

Chen F, Fan C, Gu X, Zhang H, Liu Q, Gao X, Lu J, He B, Lai X.

Med Sci Monit. 2015 Jul 21;21:2110-5. doi: 10.12659/MSM.893791.

17.

Induction of Thelper1-driven antiviral T-cell lines for adoptive immunotherapy is determined by differential expression of IFN-γ and T-cell activation markers.

Leibold J, Feucht J, Halder A, Stevanovic S, Kayser S, Handgretinger R, Feuchtinger T.

J Immunother. 2012 Nov-Dec;35(9):661-9. doi: 10.1097/CJI.0b013e318270e112.

PMID:
23090075
18.

Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.

Zhang HH, Mei MH, Fei R, Liao WJ, Wang XY, Qin LL, Wang JH, Wei L, Chen HS.

Int J Oncol. 2010 Apr;36(4):841-8.

PMID:
20198327
19.
20.

Phenotypic characteristics associated with the acquisition of HSV-specific CD8 T-lymphocyte-mediated cytolytic function in vitro.

McNally JM, Andersen HA, Chervenak R, Jennings SR.

Cell Immunol. 1999 May 25;194(1):103-11.

PMID:
10357886
Items per page

Supplemental Content

Support Center